- Inflexion has announced nine exits in 2022 with a combined valuation of £2.5 billion
- This deal marks Inflexion’s sixth exit in the healthcare and pharmaceutical services sector, generating an IRR of 25%
- Inflexion completed the buyout of Pharmaspectra in 2019 via its enterprise fund
Inflexion announced on Monday that it has sold London-headquartered Pharmaspectra to a US-listed buyer.
